Last checked at 18 Oct 2023 07:00
18 October 2023
Scancell Holdings plc
("Scancell" or the "Company")
Scancell to present at the 2023 World Vaccine Congress Europe
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces Professor Lindy Durrant, Chief Executive Officer and Chief Scientific Officer of Scancell, will be presenting at the 2023 World Vaccine Congress Europe, taking place on 17-19 October in Barcelona, Spain.
Prof Lindy Durrant, Chief Executive Officer and Chief Scientific Officer of Scancell, commented: "Following the recent announcement of positive data from the first stage in our Phase 2 SCOPE trial with SCIB1 cancer vaccine for advanced melanoma, I am excited to join other leading experts in the field to discuss the ongoing clinical progress of our two lead cancer vaccine assets SCIB1/iSCIB-1+ and Modi-1 at this prestigious forum within the vaccine community."
The title, timing and location of the presentation are as follows:
Presentation title Clinical update on the DC targeting melanoma vaccine, SCIB1 and the Modi-1 vaccine targeting citrullination
Speaker Prof Lindy Durrant
Session date and time 11:00, 19 October 2023
Location Room 2
For further information, please contact: | |
Scancell Holdings plc | +44 (0) 20 3709 5700 |
Dr Jean-Michel Cosséry, Non-Executive Chairman | |
Professor Lindy Durrant, CEO | |
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) | +44 (0) 20 7710 7600 |
Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking) | |
Nick Adams/Nick Harland (Corporate Broking) | |
Panmure Gordon (UK) Limited (Joint Broker) | +44 (0) 20 7886 2500 |
Freddy Crossley/Emma Earl (Corporate Finance) | |
Rupert Dearden (Corporate Broking) | |
ICR Consilium | +44 (0) 20 3709 5700 |
Mary-Jane Elliott/Matthew Neal/Chris Welsh | scancell@consilium-comms.com |
About the SCOPE Phase 2 clinical trial
SCOPE is an open label, multicohort, multicentre, Phase 2 study of SCIB1 in patients with advanced unresectable melanoma receiving either nivolumab with ipilimumab or pembrolizumab. SCIB1 is a deoxyribonucleic acid (DNA) plasmid vaccine encoding two CD8 epitopes from the melanoma antigens tyrosinase-related protein-2 and glycoprotein 100 (gp100), plus two CD4 epitopes from gp100. The purpose of the study is to determine whether the addition of SCIB1 to standard of care checkpoint inhibitors can improve the objective response rate (ORR) of patients with advanced melanoma relative to the checkpoint inhibitors alone. The ORR is defined as the proportion of patients with a complete or partial response at any time after the start of treatment. During the first stage of the SCOPE trial reported here, patients received SCIB1 in combination with the best treatment currently available, namely the CPIs nivolumab and ipilimumab. The First Stage milestone was protocolled to demonstrate at least a 70% ORR with an 80% power ie at least 8/15 patients responding, assessed by radiological imaging. Further information relating to the clinical trial can be found on the Company's website at https://www.scancell.co.uk
and at https://classic.clinicaltrials.gov/ct2/show/NCT04079166
About the ModiFY Phase 1/2 clinical trial
ModiFY is an open-label, multicohort, multicentre, adaptive Phase 1/2 trial of Modi-1 in patients with unresectable HGSOC, SCCHN, TNBC or RCC. The Modi-1 peptides are linked to AMPLIVANT®, a potent adjuvant which is the subject of a worldwide licensing and collaboration agreement with ISA Pharmaceuticals for the manufacturing, development, and commercialisation of Modi-1. Modi-1 stimulates CD4 T cells which may directly impact tumour growth; however, in some patients these T cells may need to be protected by CPIs if the tumour environment is highly immunosuppressive. Patients are therefore treated with Modi-1 alone or, if eligible for standard of care CPI, with Modi-1 plus a CPI.
Cohort 1 of the study confirmed the safety profile of a low dose of two citrullinated vimentin peptides. The objective for Cohort 2 of the trial was to assess the safety of the two citrullinated vimentin peptides plus an enolase peptide at a higher dose. Based on the safety data from Cohort 2, the ModiFY trial was expanded at this recommended Phase 2 dose for Modi-1 monotherapy in all four tumour types. In parallel, Cohort 3 recruited patients to receive low dose Modi-1 plus a CPI to assess safety of the combination prior to testing the higher dose of Modi-1 in Cohort 4.
Further information relating to the clinical trial can be found on the Company's website at https://www.scancell.co.uk and at https://clinicaltrials.gov/ct2/show/NCT05329532
About Scancell
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.
Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab®).
For further information about Scancell, please visit: https://www.scancell.co.uk/